STOCK MARKET BSE NSE

COVID-19 fight: ICMR approves 9 hospitals for WHO's solidarity trial in India

Over 100 countries globally have come together for the trial launched by the WHO to assess which drug can work effectively in treating Covid-19.

Published: 13th May 2020 09:04 PM  |   Last Updated: 14th May 2020 12:32 AM   |  A+A-

Medical Staff wearing PPE kit stand at LNJP hospital in delhi during the nationwide lockdown on Sunday. (Photo | Anil Shakya/EPS)

By Express News Service

NEW DELHI: The Indian Council of Medical Research (ICMR) has approved 9 hospitals--across various cities--for a solidarity trial by the World Health Organisation (WHO) to test the efficacy of repurposed drugs in the treatment of COVID-19 patients.

The five armed study that will be done on 1500 patients--severely or moderately sick with novel coronavirus--will see patients being given either Remdesivir, Chloroquine or Hydroxychloroquine, Lopinavir-Ritonavir and Lopinavir-Ritonavir with Interferon or standard of care without any of these medicines who will then be compared for results.

Over 100 countries globally have come together for the trial launched by the WHO to assess which drug can work effectively in treating Covid-19.

By enrolling patients in multiple countries--the trial which provides for both speed and scale--aims to rapidly discover whether any of the drugs slow disease progression or improve survival.

FOLLOW CORONAVIRUS LIVE UPDATES HERE

"We have approved the trials at 9 sites as of now but the overall number could reach 20-30 in a few weeks," Dr Sheela Godbole, a scientist with the ICMR and head of the trial project told this newspaper.

In India, anti-malaria drug Hydroxychloroquine along with antibiotic Azithromycin has already been recommended as part of ICMR’s clinical management guideline for COVID-19 patients in ICU despite reservations by bioethicists and limited evidence of its efficacy against the infection so far.

The government has also suggested Hydroxychloroquine for prophylaxis to people at the higher risk of contracting the infection, such as health care workers and close contacts of COVID-19 patients.

There are some reports that district and health authorities are prescribing the drug indiscriminately to people in densely populated areas such as Dharavi in Mumbai, even as the medicine can sometimes be fatal to those with prior cardiac conditions.

Meanwhile, the US pharma major Gilead which manufactures the Ebola drug Remdesevir transferred the patent to three Indian drugmaker companies, at the behest of the government, that will allow local production of the medicine in India.

The drug was not available in India so far.

Stay up to date on all the latest Nation news with The New Indian Express App. Download now

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp